CCG
LMAT icon

Chatham Capital Group’s LeMaitre Vascular LMAT Stock Holding History

Chatham Capital Group’s Portfolio LMAT Stock Details LMAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.47M Buy
46,545
+2,710
+6% +$278K 0.57% 53
2026
Q1 		$4.79M Sell
43,835
-4,210
-9% -$401K 0.69% 42
2025
Q4 		$3.9M Buy
48,045
+600
+1% +$51.7K 0.55% 59
2025
Q3 		$4.15M Sell
47,445
-2,539
-5% -$227K 0.6% 51
2025
Q2 		$4.15M Sell
49,984
-270
-0.5% -$22.6K 0.63% 47
2025
Q1 		$4.22M Buy
50,254
+1,765
+4% +$164K 0.7% 43
2024
Q4 		$4.47M Sell
48,489
-1,570
-3% -$151K 0.73% 38
2024
Q3 		$4.65M Buy
50,059
+105
+0.2% +$9.1K 0.76% 39
2024
Q2 		$4.11M Buy
49,954
+725
+1% +$53.3K 0.72% 43
2024
Q1 		$3.27M Buy
49,229
+8,770
+22% +$541K 0.6% 54
2023
Q4 		$2.3M Sell
40,459
-394
-1% -$20.6K 0.47% 64
2023
Q3 		$2.23M Sell
40,853
-206
-0.5% -$12.2K 0.5% 64
2023
Q2 		$2.76M Buy
41,059
+2,465
+6% +$150K 0.58% 54
2023
Q1 		$1.99M Buy
38,594
+26
+0.1% +$1.26K 0.44% 76
2022
Q4 		$1.77M Hold
38,568
– – 0.42% 78
2022
Q3 		$1.96M Hold
38,568
– – 0.48% 68
2022
Q2 		$1.76M Buy
38,568
+55
+0.1% +$2.46K 0.4% 75
2022
Q1 		$1.79M Buy
38,513
+566
+1% +$25.3K 0.35% 80
2021
Q4 		$1.91M Buy
37,947
+60
+0.2% +$3.1K 0.34% 76
2021
Q3 		$2.01M Sell
37,887
-436
-1% -$24.6K 0.39% 70
2021
Q2 		$2.34M Buy
38,323
+4
+0% +$212 0.45% 66
2021
Q1 		$1.87M Buy
38,319
+1,142
+3% +$53.5K 0.39% 72
2020
Q4 		$1.51M Sell
37,177
-250
-0.7% -$8.94K 0.34% 80
2020
Q3 		$1.22M Sell
37,427
-178
-0.5% -$5.34K 0.3% 80
2020
Q2 		$993K Buy
37,605
+88
+0.2% +$2.3K 0.26% 88
2020
Q1 		$935K Buy
37,517
+13,023
+53% +$402K 0.28% 85
2019
Q4 		$881K Sell
24,494
-506
-2% -$17.5K 0.22% 101
2019
Q3 		$854K Sell
25,000
-230
-0.9% -$7.35K 0.22% 103
2019
Q2 		$706K Sell
25,230
-414
-2% -$11.5K 0.18% 112
2019
Q1 		$795K Buy
25,644
+184
+0.7% +$4.91K 0.2% 102
2018
Q4 		$602K Buy
+25,460
New +$695K 0.17% 105

Other funds holding LMAT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Chatham Capital Group's LMAT Position: Q2 2026 in Review

Chatham Capital Group increased its LeMaitre Vascular (LMAT) stake by 6.2% in Q2 2026, buying an estimated $278K and bringing the position to 46,545 shares worth $4.47M. The position accounts for 0.57% of the portfolio, ranked #53.

Chatham Capital Group first reported a position in LMAT in Q4 2018 and has held it in 31 quarters since. The position peaked at $4.79M in Q1 2026. 327 funds tracked by Wall St. Rank hold LMAT as of Q2 2026.

  • Chatham Capital Group held 46,545 shares of LeMaitre Vascular worth $4.47M as of Q2 2026.
  • Chatham Capital Group bought 2,710 LeMaitre Vascular shares in Q2 2026, an estimated $278K.
  • LeMaitre Vascular made up 0.57% of Chatham Capital Group's portfolio in Q2 2026, its #53 holding.
  • Chatham Capital Group first reported a position in LeMaitre Vascular in Q4 2018 and has held it in 31 quarters since.
  • Chatham Capital Group's LeMaitre Vascular position peaked at $4.79M in Q1 2026.
  • 327 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q2 2026.

Based on Chatham Capital Group's 13F filing for Q2 2026, filed 13 Jul 2026.